Lung cancer is becoming the most common cancer globally. In China, Lung cancer has become prevalent among preceding compared to present smokers. There are many treatments for lung cancer globally like Chemotherapy, Radiotherapy, Surgery, and Targeted therapy [1] [2]. Generally, lung cancer starts in the lungs. The spongy lungs in the chest inhale oxygen and exhale carbon dioxide. Those who smoke regularly have the highest risk of lung cancer than nonsmokers. This risk increases with an increase in length, time, and the number of cigarettes smoked. Immediate treatment will help in reducing the severity of cancer. The complications of lung cancer include shortness of breath, coughing up blood, pain, and fluid in the chest. Therefore, the primary step in preventing lung cancer is quitting smoking [3].
Galexander, M., Kim, S.Y. and Cheng, H. (2020) Update 2020: Management of Non-Small Cell Lung Cancer. Lung, 198, 897-907. https://doi.org/10.1007/s00408-020-00407-5
Roviello, G., D’Angelo, A., Sirico, M., Pittacolo, M., Conter, F.U. and Sobhani, N. (2021) Advances in Anti-BRAF Therapies for Lung Cancer. Investigational New Drugs, 39, 879-890. https://doi.org/10.1007/s10637-021-01068-8
Nanavaty, P., Alvarez, M.S. and Alberts, W.M. (2014) Lung Cancer Screening: Advantages, Controversies, and Applications. Cancer Control, 21, 9-14. https://doi.org/10.1177/107327481402100102
Jones, G.S. and Baldwin, D.R. (2018) Recent Advances in the Management of Lung Cancer. Clinical Medicine (London), 18, s41-s46. https://doi.org/10.7861/clinmedicine.18-2-s41
Hori, S., Nakamura, T., Kennoki, N., Dejima, I. and Hori, A. (2021) Transarterial Management of Advance Lung Cancer. Japanese Journal of Clinical Oncology, 51, 851-856. https://doi.org/10.1093/jjco/hyab050
Kenny, P.M., King, M.T., Viney, R.C., Boyer, M.J., Pollicino, C.A., McLean, J.M., McCaughan, B.C., et al. (2008) Quality of Life and Survival in the Two Years after Surgery for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 233-241. https://doi.org/10.1200/JCO.2006.07.7230
Schabath, M.B. and Cote, M.L. (2019) Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention, 28, 1563-1579. https://doi.org/10.1158/1055-9965.EPI-19-0221
Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E. and Adjei, A.A. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594. https://doi.org/10.1016/S0025-6196(11)60735-0
Reck, M., Carbone, D.P., Garassino, M. and Barlesi, F. (2021) Targeting KRAS in Non-Small-Cell Lung Cancer: Recent Progress and New Approaches. Annals of Oncology, 32, 1101-1110. https://doi.org/10.1016/j.annonc.2021.06.001
Vinod, S.K. and Hau, E. (2020) Radiotherapy Treatment for Lung Cancer: Current Status and Future Directions. Respirology, 25, 61-71. https://doi.org/10.1111/resp.13870
Rajapakse, P. (2021) An Update on Survivorship Issues in Lung Cancer Patients. World Journal of Oncology, 12, 45-49. https://doi.org/10.14740/wjon1368
Xie, S., Wu, Z., Qi, Y., Wu, B. and Zhu, X. (2021) The Metastasizing Mechanisms of Lung Cancer: Recent Advances and Therapeutic Challenges. Biomedicine and Pharmacotherapy, 138, Article ID: 111450. https://doi.org/10.1016/j.biopha.2021.111450
Wu, S.G. and Shih, J.Y. (2018) Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non-Small-Cell Lung Cancer. Molecular Cancer, 17, 38. https://doi.org/10.1186/s12943-018-0777-1
Collins, L.G., Haines, C., Perkel, R. and Enck, R.E. (2007) Lung Cancer: Diagnosis and Management. American Family Physician, 75, 56-63.
Nagasaka, M. and Gadgeel, S.M. (2018) The Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small-Cell Lung Cancer. Expert Review of Anticancer Therapy, 18, 63-70. https://doi.org/10.1080/14737140.2018.1409624
Rossi, A. and Di Maio, M. (2016) Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Optimal Number of Treatment Cycles. Expert Review of Anticancer Therapy, 16, 653-660. https://doi.org/10.1586/14737140.2016.1170596
Burdett, S., Rydzewska, L., Tierney, J., Fisher, D., Parmar, M.K., Arriagada, R., Pignon, J.P. and Le Pechoux, C. (2016) Postoperative Radiotherapy for Non-Small Cell Lung Cancer. Cochrane Database of Systematic Reviews, 10, CD002142. https://doi.org/10.1002/14651858.CD002142.pub4
Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F. and Wong, K.K. (2014) Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases. Nature Reviews Cancer, 14, 535-546. Erratum in: Nature Reviews Cancer, 2015, 15(4): 247. https://doi.org/10.1038/nrc3775
Fois, S.S., Paliogiannis, P., Zinellu, A., Fois, A.G., Cossu, A. and Palmieri, G. (2021) Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 22, 612. https://doi.org/10.3390/ijms22020612
Rebuzzi, S.E., Zullo, L., Rossi, G., Grassi, M., Murianni, V., Tagliamento, M., Prelaj, A., Coco, S., Longo, L., Dal Bello, M.G., Alama, A., Dellepiane, C., Bennicelli, E., Malapelle, U. and Genova, C. (2021) Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 22, 2625. https://doi.org/10.3390/ijms22052625
Golding, B., Luu, A., Jones, R. and Viloria-Petit, A.M. (2018) The Function and Therapeutic Targeting of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC). Molecular Cancer, 17, 52. https://doi.org/10.1186/s12943-018-0810-4
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S. and Gil-Bazo, I. (2018) KRAS Oncogene in Non-Small Cell Lung Cancer: Clinical Perspectives on the Treatment of an Old Target. Molecular Cancer, 17, 33. https://doi.org/10.1186/s12943-018-0789-x
Hynds, R.E., Frese, K.K., Pearce, D.R., Grönroos, E., Dive, C. and Swanton, C. (2021) Progress towards Non-Small-Cell Lung Cancer Models Representing Clinical Evolutionary Trajectories. Open Biology, 11, Article ID: 200247. https://doi.org/10.1098/rsob.200247
Addeo, A., Passaro, A., Malapelle, U., Luigi Banna, G., Subbiah, V. and Friedlaender, A. (2021) Immunotherapy in Non-Small Cell Lung Cancer Harboring Driver Mutations. Cancer Treatment Reviews, 96, Article ID: 102179. https://doi.org/10.1016/j.ctrv.2021.102179
Handa, Y., Tsutani, Y. and Okada, M. (2021) Transition of Treatment for Ground Glass Opacity-Dominant Non-Small Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 655651. https://doi.org/10.3389/fonc.2021.655651
Nestle, U., Le Pechoux, C. and De Ruysscher, D. (2021) Evolving Target Volume Concepts in Locally Advanced Non-Small-Cell Lung Cancer. Translational Lung Cancer Research, 10, 1999-2010. https://doi.org/10.21037/tlcr-20-805
Van Houtte, P., Moretti, L., Charlier, F., Roelandts, M. and Van Gestel, D. (2021) Preoperative and Postoperative Radiotherapy (RT) for Non-Small Cell Lung Cancer: Still an Open Question. Translational Lung Cancer Research, 10, 1950-1959. https://doi.org/10.21037/tlcr-20-472
Chang, S., Shim, H.S., Kim, T.J., Choi, Y.L., Kim, W.S., Shin, D.H., Kim, L., Park, H.S., Lee, G.K. and Lee, C.H. (2021) Molecular Biomarker Testing for Non-Small Cell Lung Cancer: Consensus Statement of the Korean Cardiopulmonary Pathology Study Group. Journal of Pathology and Translational Medicine, 55, 181-191. https://doi.org/10.4132/jptm.2021.03.23
Łazar-Poniatowska, M., Bandura, A., Dziadziuszko, R. and Jassem, J. (2021) Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer: Recent Progress and Future Perspectives (A Narrative Review). Translational Lung Cancer Research, 10, 2018-2031. https://doi.org/10.21037/tlcr-20-704
Augustus, E., Zwaenepoel, K., Siozopoulou, V., Raskin, J., Jordaens, S., Baggerman, G., Sorber, L., Roeyen, G., Peeters, M. and Pauwels, P. (2021) Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy—The Role of Liquid Biopsies in Unraveling the Puzzle. Cancers (Basel), 13, 1675. https://doi.org/10.3390/cancers13071675
Kim, E.S., Melosky, B., Park, K., Yamamoto, N. and Yang, J.C. (2021) EGFR Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations. Future Oncology, 17, 2395-2408. https://doi.org/10.2217/fon-2021-0195
Castellanos, E., Feld, E. and Horn, L. (2017) Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, 612-623. https://doi.org/10.1016/j.jtho.2016.12.014
Bailey, C., Black, J.R.M., Reading, J.L., Litchfield, K., Turajlic, S., McGranahan, N., Jamal-Hanjani, M. and Swanton, C. (2021) Tracking Cancer Evolution through the Disease Course. Cancer Discovery, 11, 916-932. https://doi.org/10.1158/2159-8290.CD-20-1559
Qiao, N., Insinga, R., de Lima Lopes Junior, G., Cook, J. and Sénécal, M. (2021) A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-Small Cell Lung Cancer. PharmacoEconomics Open, 5, 365-383. https://doi.org/10.1007/s41669-020-00255-2
Du, X., Shao, Y., Qin, H.F., Tai, Y.H. and Gao, H.J. (2018) ALK-Rearrangement in Non-Small-Cell Lung Cancer (NSCLC). Thoracic Cancer, 9, 423-430. https://doi.org/10.1111/1759-7714.12613
Suresh, K., Naidoo, J., Lin, C.T. and Danoff, S. (2018) Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest, 154, 1416-1423. https://doi.org/10.1016/j.chest.2018.08.1048
Chevallier, M., Borgeaud, M., Addeo, A. and Friedlaender, A. (2021) Oncogenic Driver Mutations in Non-Small Cell Lung Cancer: Past, Present, and Future. World Journal of Clinical Oncology, 12, 217-237. https://doi.org/10.5306/wjco.v12.i4.217
Jablonska, P.A., Bosch-Barrera, J., Serrano, D., Valiente, M., Calvo, A. and Aristos, J. (2021) Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. Cancers (Basel), 13, 2141. https://doi.org/10.3390/cancers13092141